Healthcare DIVE March 29, 2021
Dive Brief:
- The Food and Drug Administration on Friday approved the first CAR-T cell therapy for multiple myeloma, expanding use of the powerful but complex-to-manufacture treatments beyond leukemia and lymphoma, two other blood cancers for which several other cell-based drugs are already cleared.
- Called Abecma, the newly approved therapy is for patients who have received at least four previous multiple myeloma medicines, including standard drugs like Revlimid and Darzalex. Clinical testing showed three-quarters of participants responded to treatment with Abecma, about a third of whom went into remission.
- Abecma was developed by Bluebird bio and Bristol Myers Squibb, which acquired rights through its buyout of Celgene in 2019. The therapy is now Bristol Myers’ second FDA-approved CAR-T treatment following...